Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Purchases 40,114 Shares of Stock

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. acquired 40,114 shares of the company’s stock in a transaction dated Friday, April 17th. The stock was acquired at an average cost of $3.57 per share, for a total transaction of $143,206.98. Following the completion of the acquisition, the insider directly owned 12,074,010 shares in the company, valued at approximately $43,104,215.70. The trade was a 0.33% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 20th, Broadwood Partners, L.P. acquired 40,690 shares of Oncocyte stock. The stock was acquired at an average cost of $3.88 per share, for a total transaction of $157,877.20.
• On Thursday, April 16th, Broadwood Partners, L.P. acquired 102,057 shares of Oncocyte stock. The stock was acquired at an average cost of $3.45 per share, for a total transaction of $352,096.65.
• On Tuesday, February 10th, Broadwood Partners, L.P. acquired 521,739 shares of Oncocyte stock. The stock was acquired at an average cost of $5.75 per share, for a total transaction of $2,999,999.25.

Oncocyte Price Performance

IMDX stock opened at $3.99 on Tuesday. Oncocyte Corp has a 12 month low of $2.33 and a 12 month high of $8.51. The stock has a market cap of $128.36 million, a P/E ratio of -2.46 and a beta of 1.52. The company has a fifty day simple moving average of $4.57.

Oncocyte (NASDAQ:IMDX) last issued its earnings results on Thursday, March 26th. The company reported ($0.27) EPS for the quarter. The firm had revenue of $1.14 million during the quarter.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncocyte in a report on Friday, March 27th. Wall Street Zen downgraded shares of Oncocyte from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Lake Street Capital increased their price target on shares of Oncocyte from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $12.00.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.